Tatjana Traub-Weidinger1,2, Daniel Putzer3, Elisabeth von Guggenberg2, Georg Dobrozemsky2, Bernhard Nilica2, Dorota Kendler2, Reto Bale3, Irene Johanna Virgolini4. 1. Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. 2. Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. 3. Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. irene.virgolini@i-med.ac.at.
Abstract
PURPOSE: Radiolabelled somatostatin (SST) analogues have proven useful in diagnosing tumours positive for SST receptor (SSTR). As different subtypes of SSTR are expressed on the tumour cell surface, the choice of appropriate therapeutic SST analogue is crucial. We evaluated the SSTR status of thyroid cancer patients who had signs of progressive disease comparing different SSTR ligands for PET imaging to evaluate possible further therapeutic options. METHODS: PET with (68)Ga-radiolabelled SSTR ligands DOTA lanreotide (DOTA-LAN), DOTA-Tyr(3) octreotide (DOTA-TOC) and (18)F-FDG was performed in 31 patients with thyroid cancer (TC). These 31 patients comprised 18 with radioiodine non-avid differentiated TC (DTC) including 6 papillary TC (PTC), 8 follicular TC (FTC) and 4 oxyphilic TC (oxyTC), 5 with anaplastic TC (ATC), and 8 with medullary TC (MTC). The PET results were compared in a region-based evaluation. RESULTS: All patients underwent a PET study with (68)Ga-DOTA-LAN, 28 patients with (68)Ga-DOTA-TOC and 28 patients with (18)F-FDG. A lack of SSTR expression was found in 13 of the 31 patients (42%) with negative results with both SSTR tracers in 12 patients. Ambiguous results with both SSTR tracers were observed in one patient. High tracer uptake in SSTR PET images was seen in seven DTC patients (39%; two PTC, three FTC, two oxyTC), in four ATC patients (80%) and in six MTC patients (75%). Lesions showing aerobic glycolysis on (18)F-FDG PET were found in 24 of 28 patients (86%) with corresponding positive results with (68)Ga-DOTA-LAN in 35% and with (68)Ga-DOTA-TOC in 29%. CONCLUSION: The heterogeneous SSTR profile of TC tumour lesions needs to be evaluated using different SSTR PET tracers to characterize more closely the SSTR subtype affinities in patients with progressive TC in order to further stratify therapy with SSTR therapeutics.
PURPOSE: Radiolabelled somatostatin (SST) analogues have proven useful in diagnosing tumours positive for SST receptor (SSTR). As different subtypes of SSTR are expressed on the tumour cell surface, the choice of appropriate therapeutic SST analogue is crucial. We evaluated the SSTR status of thyroid cancerpatients who had signs of progressive disease comparing different SSTR ligands for PET imaging to evaluate possible further therapeutic options. METHODS: PET with (68)Ga-radiolabelled SSTR ligands DOTA lanreotide (DOTA-LAN), DOTA-Tyr(3) octreotide (DOTA-TOC) and (18)F-FDG was performed in 31 patients with thyroid cancer (TC). These 31 patients comprised 18 with radioiodine non-avid differentiated TC (DTC) including 6 papillary TC (PTC), 8 follicular TC (FTC) and 4 oxyphilic TC (oxyTC), 5 with anaplastic TC (ATC), and 8 with medullary TC (MTC). The PET results were compared in a region-based evaluation. RESULTS: All patients underwent a PET study with (68)Ga-DOTA-LAN, 28 patients with (68)Ga-DOTA-TOC and 28 patients with (18)F-FDG. A lack of SSTR expression was found in 13 of the 31 patients (42%) with negative results with both SSTR tracers in 12 patients. Ambiguous results with both SSTR tracers were observed in one patient. High tracer uptake in SSTR PET images was seen in seven DTCpatients (39%; two PTC, three FTC, two oxyTC), in four ATC patients (80%) and in six MTC patients (75%). Lesions showing aerobic glycolysis on (18)F-FDG PET were found in 24 of 28 patients (86%) with corresponding positive results with (68)Ga-DOTA-LAN in 35% and with (68)Ga-DOTA-TOC in 29%. CONCLUSION: The heterogeneous SSTR profile of TC tumour lesions needs to be evaluated using different SSTR PET tracers to characterize more closely the SSTR subtype affinities in patients with progressive TC in order to further stratify therapy with SSTR therapeutics.
Entities:
Keywords:
68Ga-DOTA-LAN; 68Ga-DOTA-TOC; Somatostatin receptor PET imaging; Thyroid cancer
Authors: Milos Petrik; Peter A Knetsch; Roger Knopp; Giovanni Imperato; Meltem Ocak; Elisabeth von Guggenberg; Roland Haubner; Roland Silbernagl; Clemens Decristoforo Journal: Nucl Med Commun Date: 2011-10 Impact factor: 1.690
Authors: E N Klein Hesselink; D Steenvoorden; E Kapiteijn; E P Corssmit; A N A van der Horst-Schrivers; J D Lefrandt; T P Links; O M Dekkers Journal: Eur J Endocrinol Date: 2015-01-08 Impact factor: 6.664
Authors: C Waldherr; T Schumacher; M Pless; A Crazzolara; H R Maecke; E U Nitzsche; A Haldemann; J Mueller-Brand Journal: Nucl Med Commun Date: 2001-06 Impact factor: 1.690
Authors: P M Smith-Jones; C Bischof; M Leimer; D Gludovacz; P Angelberger; T Pangerl; M Peck-Radosavljevic; G Hamilton; K Kaserer; A Kofler; H Schlangbauer-Wadl; T Traub; I Virgolini Journal: Endocrinology Date: 1999-11 Impact factor: 4.736
Authors: Fabienne Iten; Beat Muller; Christian Schindler; Helmut Rasch; Christoph Rochlitz; Daniel Oertli; Helmut R Maecke; Jan Muller-Brand; Martin A Walter Journal: Cancer Date: 2009-05-15 Impact factor: 6.860
Authors: Michael Gabriel; Franz Froehlich; Clemens Decristoforo; Christian Ensinger; Eveline Donnemiller; Elisabeth von Guggenberg; Dirk Heute; Roy Moncayo Journal: Eur J Nucl Med Mol Imaging Date: 2003-11-19 Impact factor: 9.236
Authors: Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-04 Impact factor: 9.236